- Home
- BGNE vs TECK Comparison
BGNE vs TECK Comparison
Compare BGNE & TECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGNE
- TECK
- Stock Information
- Founded
- BGNE 2010
- TECK 1913
- Country
- BGNE Cayman Islands
- TECK Canada
- Employees
- BGNE N/A
- TECK N/A
- Industry
- BGNE Biotechnology: Pharmaceutical Preparations
- TECK
- Sector
- BGNE Health Care
- TECK
- Exchange
- BGNE Nasdaq
- TECK Nasdaq
- Market Cap
- BGNE 21.0B
- TECK 24.9B
- IPO Year
- BGNE 2016
- TECK N/A
- Fundamental
- Price
- BGNE $189.23
- TECK $45.00
- Analyst Decision
- BGNE Buy
- TECK Buy
- Analyst Count
- BGNE 7
- TECK 8
- Target Price
- BGNE $247.07
- TECK $64.86
- AVG Volume (30 Days)
- BGNE 281.8K
- TECK 3.2M
- Earning Date
- BGNE 11-12-2024
- TECK 10-24-2024
- Dividend Yield
- BGNE N/A
- TECK 1.64%
- EPS Growth
- BGNE N/A
- TECK N/A
- EPS
- BGNE N/A
- TECK 0.69
- Revenue
- BGNE $3,351,304,621.00
- TECK $12,329,841,958.00
- Revenue This Year
- BGNE $969.39
- TECK N/A
- Revenue Next Year
- BGNE $24.79
- TECK N/A
- P/E Ratio
- BGNE N/A
- TECK $63.65
- Revenue Growth
- BGNE 50.22
- TECK 114.29
- 52 Week Low
- BGNE $126.97
- TECK $35.25
- 52 Week High
- BGNE $248.16
- TECK $55.13
- Technical
- Relative Strength Index (RSI)
- BGNE 31.72
- TECK 38.17
- Support Level
- BGNE $189.60
- TECK $44.65
- Resistance Level
- BGNE $209.29
- TECK $51.34
- Average True Range (ATR)
- BGNE 6.42
- TECK 1.30
- MACD
- BGNE -2.10
- TECK -0.34
- Stochastic Oscillator
- BGNE 9.19
- TECK 5.16
About BGNE BeiGene Ltd.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
About TECK Teck Resources Ltd
Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 75%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024.